CVS Health brings new device, enterprise to bear on kidney disease
CVS Health is undertaking a new effort to boost patient outcomes and contain costs for chronic kidney disease and dialysis patients. The new initiative will focus on early identification of kidney disease and an expanded home dialysis offering in an effort to optimize care for patients with chronic kidney disease, the company said.
CVS Health noted that its enterprise assets and its introduction of new home hemodialysis technology positioned it to positively disrupt and reshape the kidney care space.
“In dialysis today, there is an enormous unmet medical need with high levels of mortality, frequent hospitalizations and poor quality of life for affected patients,” CVS Health executive vice president and head of CVS Specialty Alan Lotvin said. “As we explored this area it became clear that our enterprise assets from our experience with complex patient home care through Coram, the breadth of our chronic disease management capabilities with CVS Specialty and Accordant, and our deep payer relationships at CVS Caremark will enable us to create a unique value proposition to help reshape dialysis treatment.”
The company said it would be approaching the initiative in stages, beginning with efforts focused on early identification and patient education, followed by the development of a comprehensive home dialysis program. As part of the program, CVS Health said it will be initiating a clinical trial to demonstrate the safety and efficacy of a new hemodialysis device that it plans to submit to the FDA to get market clearance.
“Diagnosing kidney disease early is the only way to prevent kidney failure and cardiovascular complications,” National Kidney Foundation chief medical officer and nephrologist said Joseph Vassalotti said. “There is an urgent need to increase patient awareness of not only the disease itself but also of the treatment options available for both early and chronic kidney failure or end-stage renal disease. Many patients believe in-center dialysis is their only kidney failure treatment choice, and do not know about patient-centered options, including home dialysis or kidney transplant.”
Roughly 700,000 Americans have end-stage renal disease, and roughly half a million of them are on active dialysis, with 120,000 new cases diagnosed annually. In addition to the cost burden associated with the illness — it costs Medicare nearly $65 billion a year and another $34 billion related to patient care — its outcomes lag, with mortality rates for in-center dialysis patients 10 times higher than the general Medicare population.
“While in-center dialysis clinics are currently the most common choice for hemodialysis treatment, published clinical research has shown improved cardiac health, metabolic control, and survival for patients who are treated with longer, more frequent dialysis treatments. This treatment paradigm is best delivered in the convenience of a patient’s home,” CVS Specialty chief medical officer Bruce Culleton said. “CVS Health is uniquely positioned to build a solution that will enable us to identify and intervene earlier with patients to optimize the management of chronic kidney disease, while at the same time making home dialysis therapies a real option for more patients.”
Dr. Reddy’s names Teva vet COO
Erez Israeli succeeds 15-year COO Mukherjee
Dr. Reddy’s Labs recently made changes to its senior leadership team, spurred by the retirement of COO Abhijit Mukherjee on March 31 after 15 years with the company. Erez Israeli succeeded Mukherjee, effective April 2, becoming the company’s COO and global head of generics and pharmaceutical services and active ingredients.
In his new role, he will report to Dr. Reddy’s co-chairman and CEO G.V. Prasad. Israeli has previously served as president and CEO of Enzymotec, and has more than 25 years’ experience in the pharmaceutical industry. Twenty-three of those years were spent with Teva, where he held various leadership positions, including vice president of North American marketing and sales, vice president of Asia operations, group executive vice president, head of global quality and president and CEO of growth markets, among others.
“I would like to thank Abhijit for his valuable contribution to our company’s growth journey over the past fifteen years,” Prasad said. “I extend a warm welcome to Erez Israeli. Erez is an accomplished leader with a proven track record of achievement. His knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth.”
West-Ward brings generic Aloxi to market
West-Ward Pharmaceuticals, the U.S. subsidiary of Hikma Pharmaceuticals, has launched its generic Aloxi (palonosetron hydrochloriden injection). The drug is indicated to prevent acute nausea and vomiting associated with chemotherapy in adults. West-Ward’s generic Aloxi is the third generic of the product to launch in recent weeks.
“We are very pleased to add Palonosetron HCI Injection to our oncology portfolio,” West-Ward injectables division CEO Riad Mechlauoui said. “The launch of this product further expands our broad Injectables portfolio, bringing value to our customers and patients in the US hospital setting, as well as driving long-term, sustainable growth for our business.”
The drug, which the company is introducing in 0.25 mg/2 ml dosage strength, had a U.S. market size of $447 million for the 12 months ended January 2018.